Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
about
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsNovel agents in mantle cell lymphomaMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsFTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabCD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer TherapyInterdiction of sphingolipid metabolism to improve standard cancer therapies.The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineSurface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative diseaseThe Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.Novel targeted therapies for mantle cell lymphomaFibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cellsTranscription factor ICBP90 regulates the MIF promoter and immune susceptibility locus.Antibody therapy of pediatric B-cell lymphomaAntibody-based therapeutics for the treatment of human B cell malignanciesDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.Emerging antibody combinations in oncology.Targeted drug delivery for cancer therapy: the other side of antibodies.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Monoclonal antibodies in oncology therapeutics: present and future indications.Chemotherapy-free treatment in patients with follicular lymphoma.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.ASK1/JNK-mediated TAp63 activation controls the cell survival signal of baicalein-treated EBV-transformed B cells.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.The Gyrolab™ immunoassay system: a platform for automated bioanalysis and rapid sample turnaround.Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
P2860
Q24336378-3D0AE78F-F16B-4017-8767-C9010D677333Q27011763-718E7B46-B12B-4582-A773-8CA33D191CC4Q28075606-E15EDA5E-2814-4763-83A8-C37C9B540712Q30535265-A3ECD1DD-A100-410B-9554-30152E26A5D4Q33573605-F865B0C2-2847-47D8-80A4-54D744656D58Q33677456-D087B5BD-8C26-4DA4-8E6F-DD5DABABB277Q33862425-85B5B674-4EDB-4C40-B003-1982E842FD2AQ34373466-54E02C8D-92F9-4DA2-A88E-4BA1DB90A676Q34470502-033A2AB0-89A8-4D29-B007-C1CCCA24A64CQ35222776-62B02205-FAEF-4B6D-A077-04936AFCDC27Q35386947-F5901286-57E3-4BCE-868D-73EE14B4D92DQ35514038-0BC9515A-FC77-4204-854D-FDE3D1146FE2Q35550073-F997BB2B-6033-4169-B39B-CF233464FF52Q35815850-526A7845-A3E1-410F-AA59-F1D722CD79C3Q35889841-FF000463-1A3C-40A8-A6E8-496B69AA2B3AQ36347760-69F7AE5F-5D76-43BA-B4CE-DECD74802290Q36515036-F9BF6BED-7CD1-408B-98B7-FB950747B6D1Q36732959-C468821D-9A04-4F0F-85C2-8E1E2CA3786EQ36907540-74332898-7335-4113-A4ED-0AB94BFDED6FQ36914970-F66C22D9-FE44-4BF9-9AED-2F12CBFD23E3Q36979140-743F1814-A431-4AC0-8BBC-88395AA56399Q37129235-15C64DC0-CB37-4F6A-B8ED-7276A6EEA2C5Q37221480-01014393-3727-45D0-9EE0-2EB7E1A9489EQ37493256-CCE8A25F-CFAA-42F2-9C2D-29928285F4FDQ37893414-68FB9A29-03BA-4730-9F16-D9FD423C1B11Q38058816-22CF4F39-F672-4A16-85AC-68C53C939980Q38068494-BBA3F0FC-CE5D-456A-AA78-1EF2661D0ABEQ38071374-C98E5D2D-B9C4-4658-8EF6-F7ADACEC7E57Q38317235-AF7CCF6C-6C3E-4273-B59B-32EE952D2889Q38530254-0DCD5E7F-7E7A-4311-9283-73F05D5099E3Q38577849-B11369FF-C306-42EA-82D9-9446819A1AFCQ38809831-DF60842A-9A4D-4C67-B181-E3B5B70DFB40Q39004366-BB896710-4691-4CA7-B7BE-062CAF82F810Q39392738-FA1F564F-416D-4D68-A22E-30130C954AA7Q43830676-27A85A76-B8BC-4BBA-AC70-5097735485C0Q46430171-AF209EED-4EB5-427F-B0D1-75110A1F6CD8Q47221234-D5C6C2F8-31CE-46CB-95CF-B8BA99AB51B2Q48216696-86222BF2-3FCC-4E77-BE10-E45560C0EB9CQ50765392-F69323CB-05B2-4F79-99D7-56EA5578071A
P2860
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@ast
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@en
Combination anti-CD74
@nl
type
label
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@ast
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@en
Combination anti-CD74
@nl
prefLabel
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@ast
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@en
Combination anti-CD74
@nl
P2093
P2860
P1433
P1476
Combination anti-CD74 (milatuz ...... ivity in mantle cell lymphoma.
@en
P2093
Beth A Christian
Carl Quinion
David M Goldenberg
Erin Hertlein
Fengting Yan
Gerard Lozanski
Jungook Shin
Kristie A Blum
Lapo Alinari
P2860
P304
P356
10.1182/BLOOD-2010-08-303354
P407
P50
P577
2011-01-12T00:00:00Z